Priority 1
Family Offices
Invest in complex science with a visible evidence base, not just conviction.
Core pain: They are expanding into technical opportunities and benefit from a visible life science evidence base.
Best offer: Life Science Thesis Atlas
Use case: A family office exploring longevity therapeutics, neuroinflammation, or extracellular vesicle investments wants a public/private diligence asset.
Buyer titles
PrincipalChief Investment OfficerInvestment DirectorFamily Office Advisor
Priority 2
Emerging Venture Funds
Own a niche before larger funds notice it.
Core pain: They need to communicate a differentiated thesis clearly while their track record is still maturing.
Best offer: Category Authority Atlas
Use case: A seed fund wants to become known for AI pathology, RNA delivery, or immune-mediated disease platforms.
Buyer titles
Managing PartnerGeneral PartnerPrincipalHead of Platform
Priority 3
SSBCI and Regional Innovation Funds
Show founders, policymakers, and co-investors why your regional ecosystem matters.
Core pain: They need to communicate ecosystem expertise, public legitimacy, and sector focus to diverse stakeholders.
Best offer: Regional Innovation Authority Atlas
Use case: A state-supported fund wants to map regional biotech, diagnostics, medtech, blue-tech, or advanced manufacturing opportunities.
Buyer titles
Fund DirectorEconomic Development LeadInnovation OfficerProgram Director
Priority 4
Angel Syndicates and Physician Investor Groups
Give your members a clearer reason to believe in a technical investment thesis.
Core pain: They need members and co-investors to quickly understand and trust their technical judgment.
Best offer: Syndicate Diligence Atlas
Use case: A physician investor syndicate evaluating sepsis, fertility, diagnostics, or medical device opportunities.
Buyer titles
Syndicate LeadManaging MemberPhysician InvestorInvestment Committee Chair
Priority 5
Biotech Startups Raising Capital
Make your science easier to understand, trust, and fund.
Core pain: Their science is often complex to communicate and investors need clearer evidence of investability.
Best offer: Fundraising Evidence Atlas
Use case: A platform biotech needs to explain its mechanism, evidence, IP, market, and strategic relevance in one credible interface.
Buyer titles
CEOFounderCSOHead of BDFractional CFO
Priority 6
Pharma and Biotech Business Development Teams
Turn scattered landscape research into a reusable strategic intelligence asset.
Core pain: They need reusable, high-trust landscape intelligence for emerging scientific categories.
Best offer: Strategic Landscape Atlas
Use case: A BD team evaluating RNA delivery, exosome manufacturing, cell therapy tooling, or AI-enabled drug discovery.
Buyer titles
VP Business DevelopmentSearch and Evaluation LeadExternal Innovation LeadStrategy Director